Physician profile
Casey Dutton Triplett
NPI 1528018728
$706.48
in general payments reported to CMS, 2019-2025
13 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $381 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.74 | 2024-2025 | |
| Novo Nordisk INC | $126.72 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $70.11 | 2024-2025 | Repatha, Repatha, Otezla |
| Medtronic, INC. | $60.28 | 2025 | Symplicity G3 |
| Exact Sciences Corporation | $52.22 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $50.99 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $47.64 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $45.96 | 2024 | Farxiga |
| Pfizer INC. | $38.63 | 2024-2025 | |
| Dynavax Technologies Corporation | $33.56 | 2024-2025 | Heplisav-B |
| Astellas Pharma US INC | $16.07 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $15.37 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $15.19 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Dutton Triplett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.